NCT02239224View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

December 14, 2015

Study Completion Date

December 14, 2015

Conditions

Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions

BIOLOGICAL

Placebo

Concentrate for solution for infusion

BIOLOGICAL

ATYR1940

Concentrate for solution for infusion

Trial Locations (5)

14642

aTyr Pharma Investigative Site, Rochester

43210

aTyr Pharma Investigative Site, Columbus

Unknown

aTyr Pharma Investigative Site, Marseille

aTyr Pharma Investigative Site, Rome

aTyr Pharma Investigative Site, Nijmegen

All Listed Sponsors

lead

aTyr Pharma, Inc.

INDUSTRY

NCT02239224 - Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy | Biotech Hunter | Biotech Hunter